StockNYSE · US · USDHealthcare · Drug Manufacturers - Specialty & Generic
$BHC
Bausch Health Companies Inc.
Bausch Health is a diversified specialty pharmaceutical and medical device company that develops, manufactures and markets branded, generic and branded generic pharmaceuticals, over-the-counter products, and aesthetic medical devices. Its products address gastroenterology, hepatology, neurology and dermatology, as well as eye health through its approximately 88% ownership of Bausch + Lomb. Products are marketed directly or indirectly in approximately 90 countries. Bausch Health is headquartered in Quebec, Quebec, Canada. The company operates five segments: Salix, which sells U.S. gastrointestinal products; International, which sells branded, branded generic and over-the-counter products outside the U.S., excluding Bausch + Lomb and Solta Medical products; Solta Medical, which sells aesthetic medical devices globally; Diversified, which includes U.S. neurology, dermatology, generic and dentistry products; and Bausch + Lomb, which sells vision care, surgical and pharmaceutical products globally. Bausch Health makes money by selling these products and devices.
Barclays kept Bausch Health Companies at Equal-Weight, raising its price target to $9 from $7, a 28.6% increase. This implies a 23.6% downside from the Nov 10 close of $11.78.
The TSX gained 183.82 points to close at 35,789.09 on Friday, with gold and materials sectors leading gains. Allied Gold and Lundin Mining rose 6.8% and 5.5% respectively. The Canadian dollar fell 0.54 cents. U.S. markets saw mixed results, with the NASDAQ rebounding 1.1%.
Bausch Health (BHC) and Salix Pharmaceuticals presented research on severe alcohol-associated hepatitis at The Liver Meeting 2026. The study found a 62.0% 12-month survival rate, 69.1% rehospitalization rate, and 8.5% liver transplantation rate. The company highlights the unmet medical need in this area.
via TradingView
BHC sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BHC (Bausch Health Companies Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent BHC coverage spans financial news, earnings and market movers.
What's driving BHC
Analyst downgrade suggests the market may price in further downside pressure.
AlphAI scores every news story that mentions BHC with an AI model for sentiment and relevance, and aggregates insider trades from Bausch Health Companies Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Barclays kept Bausch Health Companies at Equal-Weight, raising its price target to $9 from $7, a 28.6% increase. This implies a 23.6% downside from the Nov 10 close of $11.78.
The TSX gained 183.82 points to close at 35,789.09 on Friday, with gold and materials sectors leading gains. Allied Gold and Lundin Mining rose 6.8% and 5.5% respectively. The Canadian dollar fell 0.54 cents. U.S. markets saw mixed results, with the NASDAQ rebounding 1.1%.
Bausch Health (BHC) and Salix Pharmaceuticals presented research on severe alcohol-associated hepatitis at The Liver Meeting 2026. The study found a 62.0% 12-month survival rate, 69.1% rehospitalization rate, and 8.5% liver transplantation rate. The company highlights the unmet medical need in this area.
Bausch & Lomb's SVP, Controller, and CAO Frederick Munsch sold 112,015 shares at $20.48 each, totaling $2.29M. He now directly owns 45,831 shares, according to an SEC Form 4 filing.
The S&P/TSX Composite Index fell 0.47% last week, but five companies saw gains of 4.60% to 27.02% after reporting earnings. Bausch Health (BHC) rose 27.02% after Q3 results, while Black Diamond (BDI), Methanex (MX), and Precision Drilling (PD) also reported strong performances. The Bank of Canada raised rates by 25 bps to 2.5%.
Bausch Health (BHC) surged 55.50% in October, driven by 13 quarters of revenue and EBITDA growth. Q2 revenue hit $2.85B, up 13%, and adjusted EBITDA rose 28% to $1.075B. Management raised 2026 guidance. The stock trades at a forward P/E of 1.38x, with analysts seeing 55.8% upside to $9.90.
Citigroup reaffirmed its Buy rating for Bausch & Lomb and increased its price target to $23 from $21, suggesting a 12.7% upside from the last close. Recent analyst price targets for the company range from $19 to $24.
Analysts raised Bausch Health's 12-month price target to $7.72, up from $7.54, implying 12% upside. The consensus rating remains 'Hold' with 1 Buy, 5 Holds, and 0 Sells. The forecasts range from $6.51 to $10.03 per share, according to 5 analysts.
Bausch Health (BHC) reached a 52-week high of $11.89 after reporting Q3 earnings of $1.77 per share, exceeding estimates. Gibson Energy (GEI) hit a 52-week high of $34.08 ahead of its Q3 2026 results release. Precision Drilling (PD) also hit a 52-week high of $151.18, reporting Q3 revenue of $532m and net income of $21m. Power Corporation (POW) and TD Bank (TD) also reached 52-week highs.